EMA/338823/2023

European Medicines Agency decision

P/0287/2023

of 4 August 2023

on the acceptance of a modification of an agreed paediatric investigation plan for obeticholic acid (Ocaliva), (EMEA-001304-PIP02-13-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

European Medicines Agency decision

P/0287/2023

of 4 August 2023

on the acceptance of a modification of an agreed paediatric investigation plan for obeticholic acid (Ocaliva), (EMEA-001304-PIP02-13-M07) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0175/2014 issued on 11 July 2014, decision P/0038/2015 issued on 20 March 2015, decision P/0310/2015 issued on 21 December 2015, decision P/0213/2017 issued on 9 August 2017, decision P/0204/2019 issued on 12 June 2019, the decision P/0041/2021 issued on 27 January 2021 and the decision P/0105/2023 issued on 13 April 2023,

Having regard to the application submitted by Advanz Pharma Limited on 20 March 2023 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 23 June 2023, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for obeticholic acid (Ocaliva), coated tablet, tablet, age-appropriate oral solid dosage form, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Advanz Pharma Limited, Suite 17, Northwood House, Northwood Avenue, Santry, D09 V504 - Dublin 9, Ireland.

EMA/PDCO/149689/2023
Amsterdam, 23 June 2023

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001304-PIP02-13-M07

Scope of the application

Active substance(s):

Obeticholic acid

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of primary biliary cirrhosis

Treatment of biliary atresia

Pharmaceutical form(s):

Coated tablet

Tablet

Age-appropriate oral solid dosage form

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Advanz Pharma Limited

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Advanz Pharma Limited submitted to the European Medicines Agency on 20 March 2023 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0175/2014 issued on 11 July 2014, decision P/0038/2015 issued on 20 March 2015, decision P/0310/2015 issued on 21 December 2015, decision P/0213/2017 issued on 9 August

2017, decision P/0204/2019 issued on 12 June 2019, the decision P/0041/2021 issued on 27 January 2021 and the decision P/0105/2023 issued on 13 April 2023.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 24 April 2023.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of primary biliary cirrhosis

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- coated tablet, tablet, age-appropriate oral solid dosage form, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of biliary atresia

2.1.1. Indication(s) targeted by the PIP

Treatment of biliary atresia

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Coated tablet

Tablet

Age-appropriate oral solid dosage form

2.1.4. Measures

Area	Description
Quality-related studies	**Study 1** Development of an age appropriate oral solid dosage form (1.5 mg mini-tablet) **Study 2** Development of an age appropriate oral solid dosage form (0.1 mg mini-tablet)

Non-clinical studies	**Study 3** Dose range-finding juvenile toxicity study **Study 4** Definitive juvenile toxicity study
Clinical studies	**Study 5** *deleted during procedure EMEA-001304-PIP02-13-M06.* ***Study 6*** *deleted during procedure EMEA-001304-PIP02-13-M03.* ***Study 7*** *deleted during procedure EMEA-001304-PIP02-13-M03.* **Study 8** Natural history data collection study from biliary atresia registries **Study 9** Randomised, placebo-controlled study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of obeticholic acid in children from birth to less than 18 years with biliary atresia, post-hepatoportoenterostomy
Extrapolation, modelling and simulation studies	Not applicable
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long-term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By June 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of primary biliary cholangitis (also known as primary biliary cirrhosis)

Authorised indication(s):

- treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA
  - Invented name(s): Ocaliva
  - Authorised pharmaceutical form(s): Film-coated tablet
  - Authorised route(s) of administration: Oral use
  - Authorised via centralised procedure